



Tamiflu® (oseltamivir phosphate) oral suspension – First-time generic

- On September 14, 2017, the FDA approved Nesher Pharmaceuticals' [AB-rated](#) generic version of Genentech's [Tamiflu \(oseltamivir phosphate\)](#) oral suspension.
- Tamiflu is indicated for the treatment of acute, uncomplicated illness due to influenza A and B infection in patients ≥ 2 weeks of age who have been symptomatic for no more than 48 hours and for the prophylaxis of influenza A and B in patients ≥ 1 year of age.
 - Tamiflu is not a substitute for early influenza vaccination on an annual basis as recommended by the Centers for Disease Control and Prevention Advisory Committee on Immunization Practices.
 - Influenza viruses change over time. Emergence of resistance substitutions could decrease drug effectiveness. Other factors (for example, changes in viral virulence) might also diminish clinical benefit of antiviral drugs. Prescribers should consider available information on influenza drug susceptibility patterns and treatment effects when deciding whether to use Tamiflu.
 - Tamiflu is not recommended for patients with end-stage renal disease not undergoing dialysis.
- Tamiflu is also available generically as oral capsules.
- Nesher Pharmaceuticals' launch plans for generic Tamiflu oral suspension are pending.



OptumRx® specializes in the delivery, clinical management and affordability of prescription medications and consumer health products. We are an Optum® company — a leading provider of integrated health services. Learn more at [optum.com](#).

All Optum® trademarks and logos are owned by Optum, Inc. All other brand or product names are trademarks or registered marks of their respective owners.

This document contains information that is considered proprietary to OptumRx and should not be reproduced without the express written consent of OptumRx.

RxNews® is published by the OptumRx Clinical Services Department.

©2017 Optum, Inc. All rights reserved.